About the Report 

Japan has one of the world’s largest pharmaceutical markets, ranking third after the United States and China. In 2024, the market expanded to 11.5 trillion yen, marking the fourth consecutive year of growth. European small- and medium-sized enterprises (SMEs) can explore several business opportunities in Japan’s pharmaceutical sector, particularly in niche markets, partnerships, and advanced technologies.

The purpose of this report is to evaluate the current status of the pharmaceutical industry in Japan. It offers insights into market trends and developments, specifically targeting EU-based small- and mid-sized companies that manufacture drugs. These companies may be looking to enter the Japanese market or strengthen their existing presence in Japan. This report also aims to inform other stakeholders in the value chain, including exporters.

Click here to access the report. 

Publication date: November 2025

Please keep in mind that this report is only accessible to EU companies which are registered to the EU Business in Japan restricted content of our website. If you are not yet a member, please register here: https://www.eu-japan.eu/eubusinessinjapan